In this issue:
- SGLT-2 vs. DPP-4 inhibitors for type 2 diabetes according to baseline HbA1c
- Mortality after reversion from prediabetes to normoglycaemia: role of modifiable risk factors
- Global prevalence of diabetic retinopathy in paediatric type 2 diabetes
- GLP-1 agonists vs. SGLT-2 inhibitors in overweight/obese individuals
- Hybrid closed-loop control in young children with type 1 diabetes
- Improving NZ’s newly funded medication uptake in Pacific patients with type 2 diabetes
- Pharmacological therapy for type 2 diabetics admitted to cardiology
- BP in adolescents and young adults with type 1 diabetes
- Implementing fully closed-loop insulin delivery for inpatients with diabetes
- CV safety with sulfonylureas as second-line drugs in type 2 diabetes
Please login below to download this issue (PDF)